Advanced Medical Isotope Corporation (trading symbol QB:ADMD)
1021 N. Kellogg St. Kennewick, Washington 99336 US
T: 509.736.4000 F: 509.736.4007 E: info@isotopeworld.com

Tags

Latest News

Advanced Medical Isotope CEO Releases Shareholder Letter Outlining New Streamlined Path to FDA Submission

(Tue, 14, Feb 2017) >> read more

 

Advanced Medical Isotope CEO Issues Letter to Shareholders Issues Full Status Update, Planned FDA Submission Pathway and Business Plan for 2017 and Beyond

(Wed, 11, Jan 2017) >> read more

 

Advanced Medical Isotope announced today that Dr. Michael Korenko, Ph. D., who formerly served as an advisor to the Board, was named as AMI's interim President and Chief Executive Officer, replacing James Katzaroff.

(Tue, 20, Dec 2016) >> read more

 

Advanced Medical Isotope announced today that it has been awarded in the Superior Court of the State of Washington in and for Benton County, a total judgment of $527,875.74 USD. 
(Fri, 2, Dec 2016) >> read more

 

 Click here for more news and updates

Social Media


Brachytherapy

Brachytherapy.

 

Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area.  According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion.  It is estimated that the U.S. market represents approximately half of the global market.  AMIC believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers.  The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer and 31,000 liver cancer.

 

Brachytherapy Market

 

Reliable sources estimate that annual sales of brachytherapy products exceed $1 billion, about half of which are in the United States. The size of the U.S. brachytherapy market for prostate cancer brachytherapy is somewhere between $90 million and $130 million per year. The market for liver and breast cancer combined is comparable.